Table 3.
Comparison of Plasma TC, LDL-C, HDL-C, and TG Statistical Indicators and Mean Differences Before and After Intervention Within P-Ea and E-Pb Groups in Two Phases
| Variables | Placebo–Vitamin E | Vitamin E–Placebo | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Mean ± SDc (mg/dL) | Median (mg/dL) |
Percentile 25 (mg/dL) |
Percentile 75 (mg/dL) |
Mean ± SD (mg/dL) |
Median (mg/dL) |
Percentile 25 (mg/dL) |
Percentile 75 (mg/dL) |
P value | |
| TCd changes in phase I | 6.06 ± 24.43 | 9.00 | −12.00 | 18.00 | −3.37 ± 33.08 | −3.50 | −23.00 | 19.00 | 0.173 |
| TC changes in phase II | −5.50 ± 16.91 | −7.50 | −18.00 | 5.50 | −3.58 ± 34.87 | −2.00 | −20.00 | 22.00 | 0.765 |
| LDL-Ce changes in phase I | 5.34 ± 24.34 | 2.40 | −9.40 | 24.60 | 0.00 ± 33.99 | −5.00 | −28.60 | 17.20 | 0.440 |
| LDL-C changes in phase II | −3.96 ± 16.29 | −3.80 | −12.30 | 6.60 | 0.84 ± 32.01 | 4.50 | −17.20 | 20.40 | 0.422 |
| HDL-Cf changes in phase I | −.65 ± 8.09 | 0.00 | −4.00 | 3.00 | 2.01 ± 10.07 | 2.50 | −3.00 | 9.00 | 0.219 |
| HDL-C changes in phase II | 0.00 ± 4.96 | 0.00 | −3.00 | 2.50 | 0.82 ± 6.55 | −1.00 | −3.00 | 3.00 | 0.565 |
| TGg changes in phase I | 3.40 ± 54.06 | 7.00 | −21.00 | 24.00 | −6.50 ± 54.00 | −4.50 | −32.00 | 17.00 | 0.437 |
| TG changes in phase II | −9.25 ± 66.31 | −0.50 | −39.50 | 34.50 | −25.74 ± 58.09 | −14.00 | −58.00 | 7.00 | 0.271 |
Notes: aPlacebo–vitamin E; bVitamin E–placebo; cStandard derivation; dTotal cholesterol; eLow density lipoprotein; fHigh density lipoprotein; gTriglyceride.